Valuation: BioNTech SE

Market Cap 20.35B 23.53B 19.01B 17.44B 32.8B 2,239B 33.32B 223B 87.53B 1,122B 88.36B 86.43B 3,711B P/E 2026 *
-14.7x
P/E 2027 * -15.3x
Enterprise Value 9.57B 11.07B 8.94B 8.2B 15.43B 1,053B 15.67B 105B 41.17B 528B 41.57B 40.66B 1,746B EV / Sales 2026 *
5.23x
EV / Sales 2027 * 5.85x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+2.72%
1 week+3.41%
Current month+3.41%
1 month-0.66%
3 months+0.70%
6 months-12.15%
Current year-1.61%
1 week 88.2
Extreme 88.2
94.41
1 month 88.2
Extreme 88.2
94.62
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+3.41%-15.88%-4.90% 23.53B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
+2.12%+3.54%+445.77%+184.49% 12.38B
Average +3.67%+10.87%+92.19%+204.74% 27.59B
Weighted average by Cap. +4.26%+12.67%+67.26%+169.21%

Financials

2026 *2027 *
Net sales 1.83B 2.12B 1.71B 1.57B 2.95B 201B 3B 20.05B 7.87B 101B 7.94B 7.77B 334B 1.86B 2.16B 1.74B 1.6B 3B 205B 3.05B 20.43B 8.02B 103B 8.09B 7.92B 340B
Net income -1.34B -1.55B -1.25B -1.15B -2.16B -148B -2.19B -14.69B -5.77B -73.93B -5.82B -5.69B -244B -1.34B -1.55B -1.25B -1.15B -2.16B -147B -2.19B -14.67B -5.76B -73.86B -5.81B -5.69B -244B
Net Debt -10.78B -12.46B -10.07B -9.23B -17.37B -1,186B -17.64B -118B -46.35B -594B -46.8B -45.77B -1,965B -9.44B -10.92B -8.82B -8.09B -15.21B -1,039B -15.46B -103B -40.6B -521B -40.99B -40.09B -1,721B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
07/08/26 USD 93.67 +2.72% 1,427,941
06/08/26 USD 91.19 -1.07% 1,349,965
05/08/26 USD 92.18 +0.91% 1,700,690
04/08/26 USD 91.35 -0.98% 2,000,003
03/08/26 USD 92.25 +1.84% 1,119,580
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
81.02EUR
Average target price
104.26EUR
Spread / Average Target
+28.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock